NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced that it will effect a 1-for-300 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"),... Read More

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: STSS) (the “Company” or “Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company’s proposal before the shareholder meeting, which is scheduled to be held on March 28, 2025, at 10:00 a.m. Eastern Time. Voting... Read More

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, As we reflect on the progress since our December update, I am excited to share the latest developments that will shape our Company’s trajectory in 2025 and beyond. With the successful closing of a $20 million financing in January, we strengthened our balance sheet by securing working capital for operating and capital expenditures and paid down our debt to... Read More

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other... Read More

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $20.0 million, before deducting underwriting fees and other estimated... Read More

Shareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery schedule Initial production and commercial deliveries to begin in Q1 2025 Sales team has signed an agreement to sell and deliver current SecureGard 1mL and 3mL inventory, with shipments and revenue that began in early December NEW YORK, Dec. 05,... Read More

Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early December Agreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025 The SecureGard agreements will strengthen the potential revenue curve for the Hungary Operation starting in 2024 NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology,... Read More

NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market (“Nasdaq”) that the Company had regained compliance with the minimum bid price requirement of $1.00 per... Read More

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it will effect a one-for-22 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on October... Read More

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company’s proposal before the shareholder meeting scheduled to be held on October 7, 2024 at 10:00 a.m. Eastern Time. “Please take a very important... Read More

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. The Bridge Financing consisted of the sale of approximately $3.5... Read More

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc . (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. The Bridge Financing... Read More

NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announced today that the Company has secured approval from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) to maintain its listing, subject to conditions outlined below.... Read More

Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU and drives expansion to support the project’s growth in the future Sharps’ portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes Sharps has exceeded the product sales commitments for the EU-based... Read More

Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company’s continued growth. Voting deadline is Friday, July 12, at 11:59 p.m. Eastern Time. NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a... Read More

Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies issues purchase orders for 1mL SecureGard ultra-low waste, smart safety syringes First 100k unit shipment is scheduled for late July, with the balance to be shipped throughout Q3 and Q4 of this year NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical... Read More

All shareholders of record as of May 17, 2024 are eligible to vote Final votes must be cast by 11:59 p.m., Eastern Time on July 12, 2024 NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW’) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, encourages its shareholders to participate actively in the... Read More

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, has made the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders were placed through a collaborative effort between Sharps... Read More

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Robert Hayes, CEO of Sharps Technology, who will share insight into... Read More

Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200 million Syringe Sales Agreement. Current Asset Purchase Agreement closing timeline is on track for expected prefillable syringe product shipments to begin by Q2 of 2025. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical... Read More

InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of $1 million into third-party escrow account. Closing on the Asset Purchase and the Syringe Sales Agreement, for product orders totaling over $200 million for the first five years of operation, is expected within the next 60 days. Based on the most likely timeframe, product shipments from... Read More

Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. Signed Syringe Sales Agreement will secure product orders totaling over $200 million for the first five years of operation. Sharps is negotiating additional pharma-segment purchase commitments for orders over the next three years, with shipments expected to... Read More

Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company’s position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S. Through the syringe Sales Agreement and the closing of the APA, Sharps will secure product orders totaling over $200 million for the first five years of operation Sharps is negotiating additional pharma-segment PFS... Read More

Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chinese-manufactured syringes in November 2023, resulting in multiple recalls and warnings for these products during the first quarter of 2024, and has advised that healthcare facilities should use plastic syringes produced elsewhere. The tariff rate on Chinese-made syringes and needles... Read More

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Roncadelle Operations , a driving force in the development of novel medical drug delivery devices, have signed a sales and distribution agreement to cooperatively sell and distribute each other’s products... Read More

NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is preparing to make the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders have been placed through a collaborative effort... Read More

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: STSS) (NASDAQ: STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party... Read More

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Roncadelle Operations , a driving force in the development of novel medical drug delivery devices with its seasoned team boasting over two decades of healthcare expertise, signed a Letter of Intent (LOI) to... Read More

NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors. The Company issued 4,418,521 shares of common... Read More

Transformative acquisition and purchase order enables Sharps to commercialize its innovative copolymer prefillable syringe systems to the healthcare market Company has a capitalization strategy through debt that has resulted in a signed term sheet with a leading middle-market lender for up to $75 Million NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an... Read More

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common... Read More

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common... Read More

$50 Million acquisition of InjectEZ strengthens manufacturing capacity and establishes Sharps’ leading position in the specialized copolymer prefillable syringe system industry Signed term sheet providing for up to $75 Million in debt financing to be used for the acquisition Nephron commits to minimum orders of over $400 Million over 10 years; $30 Million in revenue the first year and subsequent minimum orders totaling over... Read More

Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an... Read More

Company advances commercialization of Securegard smart safety syringe product line through qualification programs with a major medical device company Production of prefilled syringe products will begin in the fourth quarter of 2023 to support the co-manufacturing agreement with Nephron Pharmaceuticals NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an... Read More

Commercial revenue from specialty safety syringe systems is advancing Company to launch its vial draw syringe systems in Q2 2023 Launch of high-value, next-generation polymer-based products expected in Q3 2023 NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe... Read More

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role , Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to... Read More

NEW YORK, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with institutional investors on February 3, 2023. The aggregate gross proceeds... Read More

NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it entered into a securities purchase agreement with institutional investors for aggregate gross proceeds of approximately $3.8 million priced at the market under Nasdaq rules.... Read More

First product shipped from Sharps' facility in Hungary and first to support the Nephron Pharmaceuticals distribution and sales collaboration Sharps anticipates 1.3 million units to be commercially available in February 2023 with additional shipments to follow and new products to be added NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative... Read More

High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based syringe products for the healthcare market NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe... Read More

Company now transitions from a pre-revenue research & development start-up to a revenue generating manufacturing company Shipments to commence by the end of the year to support the recently announced distribution and sales agreement with Nephron Pharmaceuticals and its European customers NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative... Read More

Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in the first half of the year Strengthens the collaboration between Sharps and Nephron to advance the previously announced Inject-EZ startup in South Carolina in early 2023 NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- S harps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an... Read More